Acute Ischemic Stroke (AIS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Acute Ischemic Stroke Competitive Analysis Report Overview
AIS is a medical emergency caused by decreased blood flow to the brain, which results in damage to brain cells. It occurs when a blood vessel in the brain is blocked by a clot or mass, impeding blood flow to brain cells. The primary cause of ischemic stroke is atherosclerosis, the accumulation of fatty deposits (plaque) on vessel walls. These deposits can cause two types of obstruction, including cerebral thrombosis and cerebral embolism.
Key Mechanisms of Action (Marketed) | · Receptor Antagonist
· Enzyme Inhibitor · Receptor Agonist · Enzyme Replacement · Transporter Inhibitor |
Key Molecule Types (Marketed) | · Small Molecule
· Biologic |
Key Routes of Administration (Marketed) | · Oral
· Injection · Suppository · Inhalational |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
The Acute Ischemic Stroke (AIS) Marketed and Pipeline Drugs Market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for Rheumatoid Arthritis.
The report also provides actionable insights into the clinical and commercial landscapes of Acute Ischemic Stroke (AIS)drugs, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.
Key Mechanisms of Action (Pipeline) | · Enzyme Inhibitor
· Protein & Peptide Inhibitor · Receptor Agonist · Ligand Scavenger · Enzyme Replacement |
Key Molecule Types (Pipeline) | · Biologic
· Small Molecule · Oligonucleotide |
Key Routes of Administration (Pipeline) | · Injection
· Oral · Inhalational |
Top Sponsors (Marketed and Pipeline Drugs) | · Beijing Taiantan Hospital Capital Medical University
· General Hospital of Shenyang Military Region · Dongzhimen Hospital · Zhejiang University School of Medicine Hospital 2 · Hamedan University of Medical Sciences |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Acute Ischemic Stroke (AIS) Marketed Drugs Market Segmentation by Mechanisms of Action
The key MoA of the marketed drugs for Acute Ischemic Stroke (AIS) includes receptor antagonists, enzyme inhibitor, receptor agonist, enzyme replacement, and transporter inhibitor among others. Most of the marketed drugs followed receptor antagonist MoA in 2023 in the Acute Ischemic Stroke (AIS)market.
Acute Ischemic Stroke (AIS) Marketed Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of Acute Ischemic Stroke (AIS) Marketed Drugs
Acute Ischemic Stroke (AIS) Marketed Drugs Market Segmentation by Routes of Administration
The key RoA of Acute Ischemic Stroke (AIS)marketed drugs include oral, injectable, suppository, and inhalational. Most marketed drugs that were available for Acute Ischemic Stroke (AIS)were oral therapies, followed by injectables.
Acute Ischemic Stroke (AIS)Marketed Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy the Full Report to Know More about the RoA of Acute Ischemic Stroke (AIS) Marketed Drugs
Acute Ischemic Stroke (AIS) Marketed Drugs Market Segmentation by Molecule Types
In 2023, the leading molecule type for Acute Ischemic Stroke (AIS) marketed drugs was a small molecule, followed by biologic.
Acute Ischemic Stroke (AIS) Marketed Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of Acute Ischemic Stroke (AIS) Marketed Drugs
Acute Ischemic Stroke (AIS) Pipeline Drugs Market Segmentation by Mechanisms of Action
The key MoA of the drugs in the Acute Ischemic Stroke (AIS) pipeline mainly include enzyme inhibitor, protein & peptide inhibitor, receptor agonist, ligand scavenger, and enzyme replacement among others. Most of the pipeline drugs undergoing development for AIS followed enzyme inhibitor MoA in 2023.
Acute Ischemic Stroke (AIS) Pipeline Drugs Market Analysis by Mechanisms of Action, 2023 (%)
Buy the Full Report to Know More about the MoA of Acute Ischemic Stroke (AIS) Pipeline Drugs
Acute Ischemic Stroke (AIS) Pipeline Drugs Market Segmentation by Routes of Administration
The key RoA of the drugs in the Acute Ischemic Stroke (AIS)pipeline mainly include injection, oral and inhalational. In 2023, most pipeline drugs that were under development for Acute Ischemic Stroke (AIS) were injection therapies.
Acute Ischemic Stroke (AIS) Pipeline Drugs Market Analysis by Routes of Administration, 2023 (%)
Buy the Full Report to Know More about the RoA of Acute Ischemic Stroke (AIS) Pipeline Drugs
Acute Ischemic Stroke (AIS) Pipeline Drugs Market Segmentation by Molecule Types
In 2023, the leading molecule type for Acute Ischemic Stroke (AIS) pipeline drugs was biologic, followed by a small molecule. The other drugs currently in development are also oligonucleotide type.
Acute Ischemic Stroke (AIS) Pipeline Drugs Market Analysis by Molecule Types, 2023 (%)
Buy the Full Report to Know More about the Molecule Types of Acute Ischemic Stroke (AIS) Pipeline Drugs
Acute Ischemic Stroke (AIS) Marketed and Pipeline Drugs Market – Competitive Landscape
A few of the top sponsors in the Acute Ischemic Stroke (AIS) marketed and pipeline drugs market are Beijing Taiantan Hospital Capital Medical University, General Hospital of Shenyang Military Region, Dongzhimen Hospital, Zhejiang University School of Medicine Hospital 2 and Hamedan University of Medical Sciences among others. Beijing Taiantan Hospital Capital Medical University sponsored the highest number of trials in 2023.
Acute Ischemic Stroke (AIS) Marketed and Pipeline Drugs Market Analysis by Sponsors, 2023 (%)
Buy Full Report for More Sponsor Insights into the Acute Ischemic Stroke (AIS) Marketed and Pipeline Drugs Market
Segments Covered in the Report
Acute Ischemic Stroke (AIS) Marketed Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Receptor Antagonist
- Enzyme Inhibitor
- Receptor Agonist
- Enzyme Replacement
- Transporter Inhibitor
Acute Ischemic Stroke (AIS) Marketed Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Small Molecule
- Biologic
Acute Ischemic Stroke (AIS) Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Enzyme Inhibitor
- Protein & Peptide Inhibitor
- Receptor Agonist
- Ligand Scavenger
- Enzyme Replacement
Acute Ischemic Stroke (AIS) Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Biologic
- Small Molecule
- Oligonucleotide
Scope
The key components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Understand the trends shaping and driving the Acute Ischemic Stroke (AIS)market to develop business strategies.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Acute Ischemic Stroke (AIS)market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which was the leading MoA for Acute Ischemic Stroke (AIS) marketed drugs in 2023?
Most of the drugs followed receptor antagonist MoA in 2023 in the Acute Ischemic Stroke (AIS) drugs market.
-
Which was the leading molecule type for Acute Ischemic Stroke (AIS) marketed drugs in 2023?
In 2023, most of the marketed drugs for AIS were small molecules.
-
Which was the leading MoA for Acute Ischemic Stroke (AIS) pipeline drugs in 2023?
Most of the drugs followed enzyme inhibitor MoA in 2023 in the Acute Ischemic Stroke (AIS) drugs market.
-
Which was the leading molecule type for Acute Ischemic Stroke (AIS) pipeline drugs in 2023?
In 2023, most of the drugs in development for Acute Ischemic Stroke (AIS) were biologics.
-
Which are the top sponsors in the Acute Ischemic Stroke (AIS) marketed and pipeline drugs market?
A few of the top sponsors in the Acute Ischemic Stroke (AIS) marketed and pipeline drugs market are Beijing Taiantan Hospital Capital Medical University, General Hospital of Shenyang Military Region, Dongzhimen Hospital, Zhejiang University School of Medicine Hospital 2 and Hamedan University of Medical Sciences among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.